Acelot, Inc.
Acelot, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, developing first-in-class small-molecule therapies for neurodegenerative diseases with high unmet need. Its lead candidate, ACE-2223, is designed to target misfolded and aggregated TDP-43 and restore the protein's healthy form and function, addressing pathology central to amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Acelot's discovery work is powered by Resolute, an internal integrated drug-discovery platform combining AI-driven computational chemistry with structural and biological insight to drug historically intractable protein targets. Acelot publishes no public API, developer portal, SDK or machine-readable specification; its four public GitHub repositories are forks of third-party cheminformatics tooling.
Acelot, Inc. is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Drug Discovery, and Life Sciences.
Acelot, Inc.’s developer surface includes engineering blog and 8 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Build 1
SDKs, sample code, and the tooling you integrate with
Access & Security 1
Authentication, authorization, and security posture
Company 4
The organization behind the API
Other 2
Properties that don't map to a standard resource type
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.